Jazz pharma stocks.
Nov 22, 2023 · According to the issued ratings of 7 analysts in the last year, the consensus rating for Jazz Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 6 buy ratings for JAZZ. The average twelve-month price prediction for Jazz Pharmaceuticals is $204.83 with a high price target of $225.00 and a low price target of $180.00.
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company's lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, …Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. ... Pharma Stocks to Buy: Jazz Pharmaceuticals (JAZZ)This suggests that analysts have very recently bumped up their estimates for JAZZ, giving the stock a Zacks Earnings ESP of +13.68% heading into earnings season. Jazz Pharmaceuticals PLC Price and ...Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement ...On average, Wall Street analysts predict. that Jazz Pharmaceuticals's share price could reach $200.67 by Nov 9, 2024. The average Jazz Pharmaceuticals stock price prediction forecasts a potential upside of 64.48% from the current JAZZ share price of $122.00.
Investment bankUBS raised Teva Pharma (NYSE: TEVA) to Buy from Neutral and downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) to Neutral from Buy in separate notes to clients on Monday. Analysts raised the TEVA price target to $13 from $11 per share, stating the brand transition is underway and launch acceleration/pipeline …Jazz Pharmaceuticals is trading at 145.02 as of the 22nd of February 2023; that is -1.83% down since the beginning of the trading day. The stock's open price was 147.73. Stay informed about Jazz Pharmaceuticals Stock and gain insights into the value of trading Jazz Pharmaceuticals now. Get the latest Jazz Pharmaceuticals detailed stock quotes, stock trade data, stock price info, and ...Discover historical prices for JAZZ stock on Yahoo Finance. View daily, weekly or monthly format back to when Jazz Pharmaceuticals plc stock was issued.
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: These 6 analysts have an average price target of $207.83 versus the current price of Jazz ...
Jazz Pharmaceuticals. Stock Price: $132.16; ... “Jazz Pharmaceuticals added its leading drug, Xyrem, to its portfolio in 2005 with the acquisition of Orphan Medical. At that point, Xyrem was the ...A high-level overview of Jazz Pharmaceuticals plc (JAZZ) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Jazz Pharma agreed in 2021 to acquire GW Pharmaceuticals Plc, the maker of the first drug derived from the cannabis plant to win approval in the US, for $7.2 billion in cash and stock. Jazz Pharma ...Find the latest Jazz Pharmaceuticals plc (JAZZ) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Jazz Pharmaceuticals (JAZZ-0.30%) is a cross between a pharmaceutical stock and a cannabis stock. In its earlier life, it was a pharmaceutical company that was chugging along and posting some good ...
Jazz Pharmaceuticals plc : Trading strategies, financial analysis, commentaries and investment guidance for Jazz Pharmaceuticals plc Stock | Nasdaq: JAZZ | Nasdaq
Jazz Pharmaceuticals Plc ( NASDAQ: JAZZ) is studying its strategic options, including a potential sale. Jazz rose 4% in premarket trading on Friday. The pharmaceutical company is talking with ...
Investor Contacts. Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations. [email protected] Ireland: +353 1 634 3211 U.S.: +1 650 496 2717Jazz Pharmaceuticals is trading at 145.02 as of the 22nd of February 2023; that is -1.83% down since the beginning of the trading day. The stock's open price was 147.73. Stay informed about Jazz Pharmaceuticals Stock and gain insights into the value of trading Jazz Pharmaceuticals now. Get the latest Jazz Pharmaceuticals detailed stock …Jazz (JAZZ) delivered earnings and revenue surprises of -113.73% and 0.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?In today’s fast-paced world, finding moments of tranquility and inner peace can be challenging. However, with the right tools and techniques, it is possible to achieve a state of mindfulness amidst the chaos. One such tool that has gained i...Jazz Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $206.36. See the top stocks recommended by analysts >> The company has a one-year high of $169.89 ...Investor Contacts. Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations. [email protected] Ireland: +353 1 634 3211 U.S.: +1 650 496 2717
Jazz Pharmaceuticals' current valuation is significantly lower than the sector average, despite strong margins and a positive growth outlook, presenting a potential investment opportunity.The entire deal values GWPH stock at $7.2 billion, or $6.7 billion net of GW Pharma's cash. In addition to Epidiolex, Jazz will add a growing pipeline of cannabis-based drugs.Jazz Pharmaceuticals has generated $0.88 earnings per share over the last year ($0.88 diluted earnings per share) and currently has a price-to-earnings ratio of 138.6. Earnings for Jazz Pharmaceuticals are expected to grow by 13.30% in the coming year, from $15.41 to $17.46 per share. Jazz Pharmaceuticals has not formally confirmed its next ... JAZZ sits at a Zacks Rank #3 (Hold), holds a Value Style Score of A, and has a VGM Score of A. Compared to the Medical - Drugs industry's P/E of 14.7X, shares of Jazz Pharmaceuticals are trading ...Jun 23, 2023 · Benzinga. Jun. 23, 2023, 07:57 AM. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ:AVDL) Lumryz (sodium oxybate extended ... 2003. 2,800. Bruce Cozadd. https://www.jazzpharma.com. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product …Latest Jazz Pharmaceuticals PLC Stock News. As of November 13, 2023, Jazz Pharmaceuticals PLC had a $7.6 billion market capitalization, putting it in the 86th percentile of companies in the Pharmaceuticals industry. Currently, Jazz Pharmaceuticals PLC’s price-earnings ratio is 202.2.
IE00B4Q5ZN47. Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.
In February 2021, Jazz Pharmaceuticals PLC JAZZ announced a $7.2-billion buyout of GW Pharma, a huge payday for long-term GW investors. Epidiolex generated $736.4 million in sales for Jazz in 2022.In 2022, we recorded $3.7 billion in revenue, which represented an 18% increase compared to 2021. Our top-line growth was driven by the continued success of three recently launched products, Xywav ...Their JAZZ share price targets range from $135.00 to $225.00. On average, they predict the company's stock price to reach $194.86 in the next twelve months. This suggests a possible upside of 64.8% from the stock's current price. View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts.Jazz Pharma agreed in 2021 to acquire GW Pharmaceuticals Plc, the maker of the first drug derived from the cannabis plant to win approval in the US, for $7.2 billion in cash and stock.Mar 21, 2023 · Jazz Pharmaceuticals' stock is down by 14% over the past 12 months, but that is a significantly better performance than the cannabis industry over the same period, and not all that much worse than ... Jazz Pharmaceuticals laid out its 2025 vision at the J.P. Morgan Healthcare Conference last month. The company expects to generate $5 billion in revenues in 2025 and a five percentage points ...Wall Street expects a year-over-year increase in earnings on higher revenues when Jazz Pharmaceuticals (JAZZ) reports results for the quarter ended March 2023. While this widely-known consensus ...Get Jazz Pharmaceuticals PLC (JAZZ.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.
Jazz doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company's lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, …
Jazz Pharma Q4 2022 results are a miss, but 2023 outlook hits a high note; stock up 5% SA News Wed, Mar. 01 1 Comment Jazz Pharmaceuticals Non-GAAP EPS of -$0.07 misses by $1.19, revenue of $972 ...JAZZ PHARMACEUTICALS PLC is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 50% based on the firm’s …Dec 1, 2023 · Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement ... Jazz Pharmaceuticals (JAZZ) Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Jazz Pharmaceuticals yesterday and set a price target of $196.00. The company’s shares ...Jazz Pharmaceuticals. Manufacturing · Ireland · 3,100 Employees. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals is a global biopharmaceutical company. The company focuses on products for neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic and solid tum ors. Read MoreJazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company's lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, …Jazz agreed to pay $7.6 billion in a cash-and-stock transaction for GW Pharmaceuticals; at the time, that price represented a 50% premium to the latter's stock price the day before the ...Why Jazz Pharmaceuticals Stock Is Racing Higher Today. 520%. Premium Investing Services. Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley ...Jazz Pharmaceuticals' CEO is Bruce Cozadd, appointed in Jan 2003, has a tenure of 20.83 years. total yearly compensation is $17.33M, comprised of 6.9% salary and 93.1% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth $31.95M. The average tenure of the management team and the …Find real-time JAZZ - Jazz Pharmaceuticals PLC stock quotes, company profile, news and forecasts from CNN Business. ... Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) 121.76. Delayed Data. As of 4:00pm ET 01 Mar, 2022, 16:05 ET. DUBLIN, March 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2021 and provided ...
Nov 9, 2023 · Jazz revised its financial guidance for the full year 2023. Total revenues are now expected to be in the range of $3.75-$3.88 billion, a $25 million raise in the lower limit of the previously ... The stock opened at $137.25, higher than the previous close of $132.07. Throughout the day, it traded within a range of $132.82 to $137.27. The stock had a volume of 75,113 shares. JAZZ Pharmaceuticals has a market capitalization of $8.2 billion. In terms of earnings growth, JAZZ Pharmaceuticals has shown strong performance.2003. 2,800. Bruce Cozadd. https://www.jazzpharma.com. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product …Jul 24, 2021 · Jazz Pharmaceuticals generated $2.36 billion in total revenue during fiscal 2020, a 9.3% increase over fiscal 2019. However, the company's cataplexy medicine Xyrem accounted for 73.6% of its total ... Instagram:https://instagram. srock autonickel mining stockhow much does the chiropractor cost without insuranceamlm stock Jazz Pharmaceuticals: High Life 🍁 It must be 420 somewhere, since the Jazz Pharmaceuticals stock is paving its way higher and higher to ultimately reach the …Mar 1, 2022 · 01 Mar, 2022, 16:05 ET. DUBLIN, March 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2021 and provided ... mercedes stockschat etf stock Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM): Free Stock Analysis Report Assertio Holdings, Inc. (ASRT): Free Stock Analysis ReportView Jazz Pharmaceuticals PLC JAZZ investment & stock information. Get the latest Jazz Pharmaceuticals PLC JAZZ detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 25 cent coins worth money Nov 7, 2023 · (RTTNews) - Jazz Pharmaceuticals plc (JAZZ) and The University of Texas MD Anderson Cancer Center announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's ... Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement ...